154 related articles for article (PubMed ID: 33159278)
1. [
Hoberück S; Löck S; Winzer R; Zöphel K; Froehner M; Fedders D; Kotzerke J; Hölscher T
EJNMMI Res; 2020 Nov; 10(1):135. PubMed ID: 33159278
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. The effect of androgen deprivation therapy on
Onal C; Guler OC; Torun N; Reyhan M; Yapar AF
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):632-641. PubMed ID: 31732768
[TBL] [Abstract][Full Text] [Related]
4. Detection Rate of
Brumberg J; Beckl M; Dierks A; Schirbel A; Krebs M; Buck A; Kübler H; Lapa C; Seitz AK
Biomedicines; 2020 Nov; 8(11):. PubMed ID: 33217931
[TBL] [Abstract][Full Text] [Related]
5. Associations of quantitative whole-body PSMA-PET metrics with PSA progression status under long-term androgen deprivation therapy in prostate cancer patients: a retrospective single-center study.
Murthy V; Appiah-Kubi E; Nguyen K; Thin P; Hotta M; Shen J; Drakaki A; Rettig M; Gafita A; Calais J; Sonni I
Eur J Hybrid Imaging; 2023 Oct; 7(1):18. PubMed ID: 37779132
[TBL] [Abstract][Full Text] [Related]
6. 68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy.
Kesler M; Druckmann I; Levine C; Kuten J; Yossepowitch O; Even-Sapir E
Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33578990
[TBL] [Abstract][Full Text] [Related]
7. Impact of Three-Month Androgen Deprivation Therapy on [68Ga]Ga-PSMA-11 PET/CT Indices in Men with Advanced Prostate Cancer-Results from a Pilot Prospective Study.
Tseng JR; Chang SH; Wu YY; Fan KH; Yu KJ; Yang LY; Hsiao IT; Liu FY; Pang ST
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267637
[TBL] [Abstract][Full Text] [Related]
8. PSA-stratified detection rates for [
Derlin T; Schmuck S; Juhl C; Zörgiebel J; Schneefeld SM; Walte ACA; Hueper K; von Klot CA; Henkenberens C; Christiansen H; Thackeray JT; Ross TL; Bengel FM
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):913-922. PubMed ID: 29308527
[TBL] [Abstract][Full Text] [Related]
9. Parameters predicting [
Ahmadi Bidakhvidi N; Laenen A; Jentjens S; Deroose CM; Van Laere K; De Wever L; Mai C; Berghen C; De Meerleer G; Haustermans K; Joniau S; Everaerts W; Goffin K
EJNMMI Res; 2021 Apr; 11(1):41. PubMed ID: 33929626
[TBL] [Abstract][Full Text] [Related]
10. PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer.
Deijen CL; Vrijenhoek GL; Schaake EE; Vogel WV; Moonen LMF; Pos FJ; van der Poel HG; Borst GR
Clin Transl Radiat Oncol; 2021 Sep; 30():1-6. PubMed ID: 34278008
[TBL] [Abstract][Full Text] [Related]
11. Pre-test
Kraft P; Maurer T; Gafita A; Krönke M; Haller B; Weber WA; Eiber M; Rauscher I
EJNMMI Res; 2020 Feb; 10(1):6. PubMed ID: 32016584
[TBL] [Abstract][Full Text] [Related]
12. The role of (
Yilmaz U; Komek H; Can C; Altindag S
Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
[TBL] [Abstract][Full Text] [Related]
13. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
15.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
16. Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients.
Natarajan A; Agrawal A; Murthy V; Bakshi G; Joshi A; Purandare N; Shah S; Puranik A; Rangarajan V
World J Nucl Med; 2019; 18(3):244-250. PubMed ID: 31516367
[TBL] [Abstract][Full Text] [Related]
17. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.
Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L
J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Hormone-Sensitive Oligorecurrent Prostate Cancer Patients Based on Routine Use of Choline and/or PSMA PET/CT to Guide Metastasis-Directed Therapy.
Metz R; Rauscher A; Vaugier L; Supiot S; Drouet F; Campion L; Rousseau C
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980784
[TBL] [Abstract][Full Text] [Related]
19. Detection Efficacy of
Giesel FL; Knorr K; Spohn F; Will L; Maurer T; Flechsig P; Neels O; Schiller K; Amaral H; Weber WA; Haberkorn U; Schwaiger M; Kratochwil C; Choyke P; Kramer V; Kopka K; Eiber M
J Nucl Med; 2019 Mar; 60(3):362-368. PubMed ID: 30042163
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.
Ong WL; Koh TL; Lim Joon D; Chao M; Farrugia B; Lau E; Khoo V; Lawrentschuk N; Bolton D; Foroudi F
BJU Int; 2019 Nov; 124 Suppl 1():19-30. PubMed ID: 31507035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
